|
I. Overview
In comparing Viagra® and TestoCreme® ,
it is important to note they make a perfect team. Testosterone (T)
has been used topically for the treatment of low testosterone levels
for decades. However, it is important to distinguish that the timulation
of libido by testosterone is essential for drug such as Sildenafil® or Viagra® to
exert its erection enhancement effect. There are many cases in which
both compounds used simultaneously will provide a synergistic effect.
What follows is a quick review of the literature to support the
hypothesis that both Viagra® and
TestoCreme® used together have a positive action in improving
the quality of function and enjoyment for men during intercourse
II. Introduction
Erectile Dysfunction (ED) affects about 30 million men in the United
States. The available treatments for ED have undergone a steady
evolution in the past 25 years toward less invasive modalities.
These treatments have developed in parallel with the understanding
of the pathophysiologic mechanisms at work in ED. The recent introduction
of the oral agent Viagra® (V) or Sildenafil®, a type-5 phosphodiesterase
inhibitor, perhaps represents the culmination of this metamorphosis.
The ease of administration of this agent is appealing to a broad
sector of men with ED. Oral Sildenafil® therapy provides results
comparable to those of other available ED treatment modalities. (Ref.
1)
It is likely that the availability of Sildenafil® has greatly
increased the number of men who receive treatment for ED. Other
available options that predate Sildenafil include vacuum erection
devices (VEDs), intracavernosal injection therapy (ICIT), and intraurethral
prostaglandin suppository (IPS). Many men already using these therapeutic
regimens may wish to try Sildenafil® as an alternative therapy;
however, the relative efficacy of Sildenafil® compared to these
treatments remains to be defined. However the combination of Viagra® and
testosterone is extremely effective.

III. Testosterone Effect on Aging Men
Use of Viagra® can augment the action of lower testosterone
levels. Aging men develop a significant loss of muscle strength
that occurs in conjunction with a decline in serum testosterone
concentrations. Increasing testosterone concentrations in elderly
men increases skeletal muscle protein synthesis and strength. This
increase may be mediated by stimulation of the intramuscular IGF-I
system. (Ref. 2)
There is considerable interest in the relationship between testosterone
and sexual behavior in men, but the few available data bearing on
this issue are inconclusive. Testosterone concentration did not
correlate with the sexual activity and interest variables. These
results provide evidence that differences among men in circulating
testosterone concentration within the normal range do not account
for differences in sexual activity and interest. It is also unlikely
that variations in sexual activity account for differences in testosterone
concentration. (Ref. 3) It appears that a factor
more sensitive than total testosterone levels can be used as a marker
for ED.

IV. DHT and Sex Drive
Dihydrotestosterone is capable of maintaining sex functions in
hypogonadal men. There is no evidence that androgen administration
in excess of the individually determined critical levels further
enhances sex functions. In view of the rapidly declining blood levels
of androgens with the available parenteral testosterone ester preparations,
the results suggest that hypogonadal patients may benefit from a
more frequent administration of these preparations. (Ref.
4) However, if it is the conversion of testosterone to DHT
which stimulates libido, then any increase in activity of the enzyme
which converts testosterone to higher levels of DHT will stimulate
sexual desire.
Androgens are essential for the expression of normal libido in
the male, but their role in the maintenance of the erectile response
in humans is controversial. In the rat castration induces:
- loss of penile reflexes
- considerable reduction in the erectile response to
electric field stimulation (EFS) of the cavernosal
nerve.
Both affects can both be reversed by testosterone replacement.
Castration reduced the EFS-induced erectile response by 50% in comparison
with intact rats and testosterone restored this decrease to normal.
When finasteride was given to these testosterone-treated castrate
rats, erectile response was not restored. DHT was as effective as
testosterone in restoring response to EFS in castrates and this
effect was not decreased by finasteride. Nitric oxide synthase activity
in the penile body was measured by the arginine-citrulline conversion
and was found to correlate with the EFS determinations. These results
show that DHT is the active androgen in the prevention of erectile
failure seen in castrated rats, and suggest that this effect may
be mediated, at leastpartially, by changes in nitric oxide synthase
levels in the penis. (Ref. 5)
The effects of supraphysiological levels of testosterone, used
for male contraception, on sexual behavior and mood were studied
The testosterone administration increased trough plasma testosterone
levels by 80%, compatible with peak testosterone levels 400-500%
above baseline. Various aspects of sexuality were assessed using
sexuality experience scales (SES) questionnaires at the end of each
4-week period while sexual activity and mood states were recorded
by daily dairies and self-rating scales. In both groups there was
a significant increase in scores in the Psychosexual Stimulation
Scale of the SES (SES 2) following testosterone administration,
but not with placebo. The SES 2 results suggest that sexual awareness
and arousability can be increased by supraphysiological levels of
testosterone. However, these changes are not reflected in modifications
of overt sexual behavior, which in eugonadal men may be more determined
by sexual relationship factors. This contrasts with hypogonadal
men, in whom testosterone replacement clearly stimulates sexual
behavior. There was no evidence to suggest an alteration in any
of the mood states studied, in particular those associated with
increased aggression. We conclude that supraphysiological levels
of testosterone maintained for up to 2 months can promote some aspects
of sexual arousability without stimulating sexual activity in eugonadal
men within stable heterosexual relationships. Raising testosterone
does not increase self-reported ratings of aggressive feelings. (Ref.
6)
The search for a more natural T form has resulted in the development
of s Testosterone cream, TestoJel® based on soy proteins. TestoJel
is a transdermal system for delivering natural testosterone ( identical
to that secreted by the testicles) directly into the blood stream
without pills or shots. Therapeutic levels of T hormone (5mg/day)
are achieved with only 1-2 tsp. per day.
This dose containing approximately 40-80mg of testosterone is delivered
to a testosterone deficient male patient, who can apply it to their
scrotum twice a day. By monitoring blood levels of free and total
testosterone, absorption is determined and the dose can be adjusted
to each individuals needs. Any level over 450 ng/dl is associated
with normal sexual function (normal 270-1270 ng/dl). Men claim that
their ability to ejaculate frequently improves and their frequency
of erections in the morning increase as well. Men with levels in
the normal range, report that they also have an increased sense
of "well-being" and find it easier to build muscle tissue.

V. TestoCreme® and Viagra®
Prior to the development of TestoCreme® and
TestoJel® , the controlled delivery of testosterone to
hypogonadal men was provided by TestoDerm®, a self-adherent
scrotal testosterone system to provide programmed testosterone
delivery through the uniquely permeable scrotal skin. Androderm® was
developed as a generic drug containing 5 grams of testosterone
for use anywhere on the body .
The responses of men to supplementary testosterone and its metabolites
by trans scrotal testosterone systems of varying testosterone content
were compared with the response to 200 mg of testosterone enanthate.
Daily transscrotal testosterone system administration resulted in
a rapid increase of testosterone and bioavailable T or free T. The
free testosterone levels are non-sex hormone binding globulin-bound
testosterone are biologically active. Testosterone levels peak at
two hours, followed by a slow decline over 23 hours, resembling
the diurnal variation of endogenous testosterone. One year of daily
transscrotal testosterone system therapy demonstrated continued
reliable absorption of testosterone and suppression to normal of
the luteinizing hormone (LH) in two of three patients.
There was a greatly disproportionate increase of serum dihydrotestosterone
( DHT) over testosterone, suggesting 5-alpha reduction at the scrotal
site. The subjects reported marked subjective improvement. Thus,
the transscrotal testosterone system is a novel, effective, and
well-tolerated method of delivering testosterone to hypogonadal
patients. (Ref. 7)
However, patch testosterone preparations fall off easily, they
are large and bulky and crinkle with movement. Although they are
expected to deliver adquate testosterone with one patch, most of
the research supporst two or three patch use for younger men. The
cost is prohibitive and the release of AndroGel® creates a similar
problem. TestoCreme® requires
only 1/2 to 1 gram of cream application for delivery of a comparable
amount of testosterone.
In summary, transdermal testosterone has been found to be both
safe and efficacious for hormone replacement or supplementation
for men who are deficient. The use of TestoCreme® transdermal
testosterone-based cream offers a simple alternative method of treating
hypogonadism TestoCreme® has
been shown to be both effective in raising free and total T and
is more convenient for patients than other methods of testosterone
delivery. (Ref. 8)



VI. References
1. Anthony Gauthier, MD, et al. Relative Efficacy
of Sildenafil Compared to Other Treatment Options for Erectile Dysfunction
[South Med J 93(10):962-965, 2000. © 2000 Southern Medical
Association]
2. Urban RJ, Bodenburg YH, Gilkison C, Foxworth
J, Coggan A.R.Wolfe RR, Ferrando A. Testosterone administration
to elderly men increases skeletal muscle strength and protein synthesis.
Am J Physiol 1995 Nov; 269(5 Pt 1): E820-6
3. Brown WA, Monti PM, Corriveau DP . Serum testosterone
and sexual activity and interest in men. Arch Sex Behav 1978 Mar;
7(2): 97-103
4. Gooren LJ. Androgen levels and sex functions
in testosterone-treated hypogonadal men. Arch Sex Behav 1987 Dec;16(6):463-73
5. Lugg JA, Rajfer J, Gonzalez-Cadavid NF. Dihydrotestosterone
is the active androgen in the maintenance of nitric oxide-mediated
penile erection in the rat. Endocrinology 1995 Apr;136(4):1495-501
6. Anderson RA, Bancroft J, Wu FC. The effects
of exogenous testosterone on sexuality and mood of normal men. J
Clin Endocrinol Metab 1992 Dec;75(6):1503-7
7. Korenman SG, Viosca S, Garza D, Guralnik M,
Place V, Campbell P, Davis SS . Androgen therapy of hypogonadal
men with transscrotal testosterone systems. American Journal of
Medicine 1987 Sep;83(3):471-8
8. Kryger, AH. The Effect of Administration of
a Testosterone Cream in Hypogonadal men. (unpublished). Study available
on www.TestoCreme.com .
Questions about this article? Please send
to: Drk@wellnessmd.com |